Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Dyadic International stock

Own Dyadic International stock in just a few minutes.

Dyadic International, Inc is a biotechnology business based in the US. Dyadic International shares (DYAI) are listed on the NASDAQ and all prices are listed in US Dollars. Dyadic International employs 6 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Dyadic International

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DYAI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Dyadic International share price

Use our graph to track the performance of DYAI stocks over time.

Dyadic International shares at a glance

Information last updated 2021-04-30.
52-week range$4.46 - $10.98
50-day moving average $5.15
200-day moving average $5.88
Wall St. target price$11.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.26

Buy Dyadic International shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Dyadic International stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dyadic International financials

Revenue TTM $1.6 million
Gross profit TTM $176,990
Return on assets TTM -18.44%
Return on equity TTM -29%
Profit margin 0%
Book value $1.04
Market capitalisation $123.7 million

TTM: trailing 12 months

Shorting Dyadic International shares

There are currently 1.1 million Dyadic International shares held short by investors – that's known as Dyadic International's "short interest". This figure is 3.7% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Dyadic International shares can be evaluated.

Dyadic International's "short interest ratio" (SIR)

Dyadic International's "short interest ratio" (SIR) is the quantity of Dyadic International shares currently shorted divided by the average quantity of Dyadic International shares traded daily (recently around 1.4 million). Dyadic International's SIR currently stands at 0.73. In other words for every 100,000 Dyadic International shares traded daily on the market, roughly 730 shares are currently held short.

However Dyadic International's short interest can also be evaluated against the total number of Dyadic International shares, or, against the total number of tradable Dyadic International shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dyadic International's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Dyadic International shares in existence, roughly 40 shares are currently held short) or 0.0546% of the tradable shares (for every 100,000 tradable Dyadic International shares, roughly 55 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Dyadic International.

Find out more about how you can short Dyadic International stock.

Dyadic International share dividends

We're not expecting Dyadic International to pay a dividend over the next 12 months.

Dyadic International share price volatility

Over the last 12 months, Dyadic International's shares have ranged in value from as little as $4.46 up to $10.98. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dyadic International's is 0.0552. This would suggest that Dyadic International's shares are less volatile than average (for this exchange).

Dyadic International overview

Dyadic International, Inc. , a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd. ; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S. L.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site